Company profile
Auricula Biosciences Inc.
Privately held: no public share price (Private KRAS-focused biotech created 2022 by TVM Capital Life Science and Syndivia. [resolved 2026-08-05 by resolve-null-is-public; source: https://tvm-capital.com/syndivia-and-tvm-capital-life-science-announce-creation-of-auricula-biosciences-to-develop-innovative-therapy-for-patients-with-k-ras-mutant-malignancies/]) · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | KRAS (mutant; tumor-selective delivery via macropinocytosis) with aSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.